Wave Life Sciences reports early-stage data showing monthly dosing possible for RNA editing therapy in AATD
Wave Life Sciences announced an updated cut of data from its early-stage study of an RNA editing treatment aimed at alpha‑1 antitrypsin deficiency (AATD).
The new data suggest the genetic therapy could be administered on a monthly schedule, which may simplify treatment compared with less frequent dosing regimens.
The study remains early in development, and further clinical testing will be required to confirm safety and efficacy before the approach can move toward regulatory review.
Wave’s CEO highlighted the potential of the monthly dosing concept as a step toward more convenient therapy options for patients with AATD.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Wave aims for monthly dosing with RNA editing treatment for AATD”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that